Disc Presented Updated Results From Phase 2 BEACON Study Of Bitopertin And Other Programs At The 65th ASH Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Disc Medicine presented updated results from its Phase 2 BEACON study of Bitopertin at the 65th ASH Annual Meeting, showing significant reductions in PPIX and improvements in sunlight tolerance. Bitopertin was well-tolerated with stable hemoglobin levels. Additionally, Disc announced positive data from a phase 1b study of DISC-0974 in myelofibrosis patients, noting improvements in hemoglobin and reduced transfusion needs.
December 12, 2023 | 7:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Disc Medicine's positive study results for Bitopertin and DISC-0974 could potentially lead to increased investor confidence in IRON, anticipating future revenue growth from these treatments.
The positive results from the Phase 2 BEACON study and the phase 1b study of DISC-0974 are likely to be viewed favorably by investors, as they indicate progress in the company's pipeline and potential for future revenue streams. This could lead to a short-term positive impact on IRON's stock price, as the market reacts to the potential of these treatments to succeed in later-stage trials and eventually reach the market.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80